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Co-secreting TSH and GH 
pituitary adenoma
L H Adams and D Adams
A case of a co-secreting TSH and growth 
hormone pituitary adenoma presenting with a 
thyroid nodule
Laura Hamilton Adams and Derick Adams
Department of Endocrinology, Diabetes, and Metabolism, University of Kentucky, Lexington, Kentucky, USA
Summary
Co-secreting TSH and growth hormone pituitary adenomas are rare. We present a case of a 55-year-old woman who 
presented with symptoms of neck fullness. Ultrasound revealed multiple thyroid nodules and examination revealed 
several clinical features of acromegaly. She was found to have a co-secreting TSH and growth hormone pituitary 
macroadenoma. She underwent surgical resection followed by gamma knife radiation, which resulted in complete 
remission of her TSH and GH-secreting adenoma.
Background
TSH and growth hormone co-secreting pituitary adenomas 
are a rare phenomenon. TSH-secreting pituitary adenomas 
account for less than 3% of all pituitary adenomas. They 
typically present with either symptoms of tumor growth 
or symptoms of hyperthyroidism. The patient in this 
case initially presented with a thyroid nodule and was 
eventually found to have a co-secreting TSH and GH 
pituitary macroadenoma. Our patient achieved remission 
without somatostatin analog therapy, which is unlike 
many other cases of TSH and GH co-secreting pituitary 
adenomas (1, 2, 3).
Case presentation
A 55-year-old woman with a medical history significant 
only for hypertension initially presented to her primary 
care physician with complaints of fullness in her upper 
neck for the past several months. She complained of no 
other symptoms at the time though she was concerned she 
may have a thyroid nodule. A thyroid ultrasound showed 
a heterogeneous and enlarged thyroid gland with several 
small cysts throughout the gland and two thyroid nodules. 
One nodule was a subcentimeter right-sided nodule, which 
was mixed cystic and solid with grade 1 vascularity without 
calcifications (Fig.  1). The other was a left-sided primarily 
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Learning points:
 • TSH-secreting pituitary adenomas are rare and about one-third co-secrete other hormones.
 • Thyroid nodules are common in acromegaly and can be the presenting sign of a growth hormone-secreting 
pituitary adenoma.
 • In the workup of acromegaly, assessment of other pituitary hormones is essential, even in the absence of 
symptoms of other pituitary hormone dysfunction.
 • Complete remission of co-secreting GH and TSH pituitary macroadenomas is possible with surgery and radiation 
alone.
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cystic nodule, which measured 2.3 cm in maximal dimension 
(Figs 2 and 3). Thyroid function tests were then checked and 
revealed a TSH of 1.7 µIU/mL (normal range: 0.5–4.0) and 
free T4 of 1.8 ng/dL (normal range: 0.5–1.1). Total T3 was 
270 ng/dL (normal range: 85–190). She was subsequently 
referred to Endocrinology for abnormal thyroid function 
tests and thyroid nodules. Upon examination, the patient 
was noted to have an enlarged jaw, coarse facial features, 
soft tissue thickening of her face and hands and bony 
enlargement of her hands and feet. The patient revealed 
that over the past 5 years, her shoe size had increased from 
a size 6 to a size 8. She had also recently noticed that her 
high school ring only fit around the tip of her fourth digit. 
She had had cessation of menses at the age of 42 years. She 
had also noted occasional headaches but had not had any 
recent vision loss. She had no arthralgias and no symptoms 
of obstructive sleep apnea. Additionally, she had no heat 
intolerance, palpitations or weight loss. Her height was 
165 cm and weight was 74.2 kg. BMI was 27 kg/m2. Her heart 
rate was 77 bpm and blood pressure was 139/94.
Investigation
Thyroid function tests were repeated and showed a TSH 
of 1.27 µIU/mL (normal range: 0.5–4.0) and free T4 by 
equilibrium dialysis was 3.9 ng/dL (normal range: 0.8–2.0). 
Due to a suspicion for acromegaly based on examination, 
a growth hormone level and insulin like growth factor 
were checked. Growth hormone was elevated at 17 ng/mL 
(normal range: 0.03–10.00). Insulin-like growth factor was 
elevated at 1292 ng/mL (normal range for age: 53–287). 
Other pituitary function was assessed with a prolactin, 
which was 25.4 ng/mL (normal range: 4–20), luteinizing 
Figure 1
Patient’s initial thyroid ultrasound images. Sagittal orientation of the 
right-sided subcentimeter nodule, which is mixed solid and cystic.
Figure 2
Patient’s initial thyroid ultrasound images. Left-sided cystic nodule in 
sagittal orientation. It measures 2.31 cm longitudinally and 1.75 cm in 
anterior–posterior dimension.
Figure 3
Patient’s initial thyroid ultrasound images. Left-sided cystic nodule 
measuring 1.88 cm in the transverse plane.
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hormone, which was 1.6 mIU/mL (normal post-
menopausal range: 10–60), follicle stimulating hormone 
which was 7.3 mIU/mL (normal post-menopausal range: 
16.7–113.6). ACTH stimulation test was normal with 
serum cortisol rising to 22.2 µg/dL 60 min after 250 µg 
of synthetic ACTH. She underwent formal visual field 
testing that showed no peripheral vision deficits. MRI 
of the pituitary showed a large sellar mass measuring 
3.8 cm × 4.1 cm compressing the optic chiasm and optic 
nerves and invading into the left cavernous sinus (Fig. 4) 
consistent with the diagnosis of pituitary macroadenoma.
Treatment
Given the size of the macroadenoma and compression 
of the optic chiasm, the patient was urgently referred 
to neurosurgery for evaluation. She underwent 
transsphenoidal resection of the macroadenoma (Figs 5 
and 6). Post operatively, the patient developed polyuria 
and was thought to have central diabetes insipidus. 
She was started on oral desmopressin 0.05 mg nightly. 
Additionally, as a precaution, she was also started 
on hydrocortisone 20 mg every morning and 10 mg 
every evening in the event that she developed adrenal 
insufficiency after resection of the large macroadenoma. 
At 6 weeks postoperatively, her 8 a.m. cortisol was 13 µg/dL 
(normal range: 6–25) after holding hydrocortisone for 
36 h. Hydrocortisone was then discontinued. Her other 
labs 6  weeks after surgery showed a prolactin level of 
6.7 ng/dL (normal range: 4–20), a free T4 of 0.7 ng/dL 
(normal range: 0.5–1.1) and a TSH of 0.8 µIU/mL (normal 
range: 0.5–4.0). Luteinizing hormone remained low 
at 0.7 ng/dL (normal post-menopausal range: 10–60) 
as did follicular-stimulating hormone at 3.2 mIU/mL 
(normal post-menopausal range: 16.7–113.6). Insulin-
like growth factor had come down to 242 ng/mL (normal 
range: 53–287). About 2  months post operatively, her 
Figure 4
Preoperative T1-weighted sagittal MRI showing a heterogeneously 
enhancing 3.8 cm × 4.1 cm mass in the sella, which elevates and 
compresses the optic chiasm.
Figure 5
Pathology specimen of the patient’s pituitary adenoma showing a typical 
solid growth pattern. Micrographs complementary of Dr Dianne Wilson 
MD, Department of Pathology, University of Kentucky.
Figure 6
Higher power micrograph of the patient’s pituitary adenoma showing 
small, monomorphous cells of the neuroendocrine cytophenotype. 
Micrographs complementary of Dr Dianne Wilson MD, Department of 
Pathology, University of Kentucky.
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desmopressin was held for a trial off of the medication. 
After holding desmopressin for 1 week, her serum sodium 
increased to 145 mmol/L (from 143 mmol/L 2  weeks 
before), plasma osmolality was 297 mosmol/kg and urine 
osmolality was 602 mosmol/kg. Partial DI was suspected 
and she was restarted on desmopressin as a spray at 
10 µg nightly.
Outcome and follow-up
MRI of the pituitary 3  months post operatively that 
showed evidence of residual tumor along the left aspect 
of the sella (Fig.  7). Given her residual tumor on MRI, 
she was treated with gamma knife radiation 4  months 
after transsphenoidal resection. Her 6-month post-
operative IGF-1 level was normal at 206 ng/mL (normal 
range: 53–287). She remained without symptoms and 
comorbidities of acromegaly including the absence of 
OSA symptoms, signs of left ventricular dysfunction, or 
osteoarthritis. One year post operatively, her insulin like 
growth factor was 107 ng/mL, well within the normal 
range for age of 53–287 ng/mL. Her MRI done 10 months 
after gamma knife radiation showed the area of residual 
tumor was of similar size (16 mm in maximal diameter) 
but more confluent in appearance. Her TSH and free 
T4 remained normal at 0.79 µIU/mL (normal range: 
0.4–4.2) and 1.0 (normal range: 0.9–1.6), respectively. 
She continued to have central hypogonadism, which 
was suspected to be from hormonal hyposecretion from 
the pituitary mass. In terms of her partial central DI, she 
failed another trial off desmopressin 15  months post 
operatively. After holding desmopressin for 3  days and 
remaining NPO for 8–10 h overnight, her serum sodium 
was 149 mmol/L, plasma osmolality was 293 mosmol/
kg and her urine osmolality was 486 mosmol/kg. She 
was continued on desmopressin 10 µg intranasally daily 
until 18 months after transsphenoidal resection. Repeat 
thyroid ultrasound done 9 months after transsphenoidal 
resection showed no evidence of the left-sided cyst 
and a stable appearance and size of her right-sided 
subcentimeter nodule. It did not meet criteria for fine 
needle aspiration. Two years after gamma knife radiation, 
MRI showed no evidence of tumor progression and IGF-1 
level was 69 ng/mL (normal range: 53–287).
Discussion
This patient presented initially with a thyroid nodule 
and was found to have a TSH- and GH-secreting pituitary 
macroadenoma. This represents a unique presentation 
of a unique disease. TSH-secreting pituitary adenomas 
are rare. Their prevalence is estimated at about 2.8% 
of all pituitary adenomas (4). Not uncommonly, they 
co-secrete other pituitary hormones including growth 
hormone (in about 16% of cases), prolactin (in about 
10% of cases), and gonadotropins (in about 1% of 
cases) (5). TSH-secreting adenomas are typically benign, 
however, more than 60% of them are locally invasive as 
our patient’s was (6). TSH-secreting pituitary adenomas 
typically present with either symptoms of tumor growth 
like headache or visual field disturbance or symptoms of 
hyperthyroidism (4). While thyroid nodules are common 
in patients with TSHomas, they are not typically the 
presenting sign. Our patient presented with a thyroid 
nodule. She had occasional nonspecific headaches but 
no visual changes, palpitations, weight loss or tremor. In 
hindsight, she had multiple reasons to have structural 
thyroid disease.
Both TSH-secreting pituitary adenomas and growth 
hormone-secreting pituitary adenomas are associated 
with goiters. Acromegalic patients on average have larger 
thyroid glands compared to non-acromegalic controls (7). 
Goiters are more common as well with a prevalence of 
25% in patients with acromegaly and 8.3% in controls 
(7). Both TSH- and GH-secreting pituitary adenomas are 
also associated with an increased incidence of thyroid 
Figure 7
T1-weighted sagittal MRI done 3 months post operatively showing 
absence of the sellar mass but some enhancing tissue present along the 
inferior aspect of the sella representing residual tumor.
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nodules. One case series of patients with TSH-secreting 
adenomas reported a frequency of thyroid nodules of 
64% (6). The prevalence of thyroid nodules in patients 
with GH-secreting adenomas has been found to be 
similar at 64.6% in one cross sectional study (7). These 
figures compare with the prevalence of thyroid nodules 
in the general population, which has been reported to 
be about 30%. The mechanism by which acromegaly 
causes thyroid as well as other organ enlargement likely 
has to do with the fact that IGF-1 is associated with both 
increased cellular proliferation and decreased cellular 
apoptosis (8). Follicular cells of the thyroid, specifically, 
have IGF-1 receptors (7). However, serum IGF-1 levels 
are not necessarily correlated with the presence of 
thyromegaly (8). Our patient’s large, predominantly 
cystic thyroid nodule resolved completely after surgical 
resection of her pituitary tumor. It is uncertain whether 
this was due to the treatment of acromegaly and central 
hyperthyroidism or if this was simply the natural history 
of her thyroid nodule. Her remaining nodule was <1 cm 
without concerning sonographic characteristics and did 
not require biopsy.
Thyroid cancer has rarely been found in patients with 
TSH-secreting adenomas (4). The frequency of thyroid 
cancer in patients with acromegaly, however, has been 
debated. Some studies have shown an increased rate of 
thyroid cancer in patients with acromegaly compared to 
controls without acromegaly (7). In one meta-analysis, 
the pooled odds ratio for thyroid cancer in acromegaly 
compared to normal controls was found to be 6.7. 
However, this same meta-analysis showed no difference 
in the relative risk of thyroid malignancy in acromegalics 
with thyroid nodules compared to non-acromegalics with 
thyroid nodules (9). Thus, the increased risk of malignancy 
in patients with acromegaly may just be due to the fact 
that they have more nodules. The 2014 Endocrine Society 
guidelines on treatment of acromegaly recommend a 
thyroid ultrasound in patients with acromegaly only if 
there is palpable thyroid nodularity.
In terms of treatment, our patient’s GH- and TSH-
producing pituitary macroadenoma went into remission 
after surgery and gamma knife radiation alone. The 
first-line treatment for both TSH and growth hormone-
secreting pituitary adenomas is surgical resection. 
However, less than 60% of patients with TSH-secreting 
pituitary macroadenomas and less than 50% of 
GH-secreting macroadenomas achieve remission with 
surgery alone (4). Radiation therapy is used in addition 
to surgery to halt tumor growth and achieve biochemical 
remission. In patients with TSH-secreting pituitary 
adenomas, about two-thirds will need only surgery and 
radiation (2). The medical treatment used to normalize 
TSH and FT4 levels is somatostatin analogs like octreotide. 
This is effective in about 90% of patients with TSH-
secreting pituitary adenomas (4). Unlike many other case 
reports of co-secreting TSH and GH pituitary adenomas, 
our patient did not require somatostatin analog therapy 
(1, 2, 3).
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